Peripheral blood adipokines and insulin levels in patients with Alzheimer’s disease: A replication study and meta-analysis

Current Alzheimer Research

Volumn 13, Issue 3, 2016, Pages 223-233

  Ma, Jing ^a   Zhang, Wei ^a   Wang, Hui Fu ^b   Wang, Zi Xuan ^a   Jiang, Teng ^c   Tan, Meng Shan ^d   Yu, Jin Tai ^a,b,d,e   Tan, Lan ^a,b,d  

^a QINGDAO UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d OCEAN UNIVERSITY OF CHINA   (China)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adipokines; Adiponectin; Alzheimer s disease; Insulin; Leptin; Plasma; Serum

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; INSULIN; LEPTIN;

ALZHEIMER DISEASE; ARTICLE; HUMAN; INSULIN BLOOD LEVEL; META ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUBLISHING; REPLICATION STUDY; BLOOD; FEMALE; MALE; RISK FACTOR;

ADIPOKINES; ALZHEIMER DISEASE; BIOMARKERS; FEMALE; HUMANS; INSULIN; MALE; RISK FACTORS;

EID: 84960094032     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720501303160217111434     Document Type: Article

References (58)

1. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. New Eng J Med 348(14): 1356-64 (2003).
2. Jiang T, Yu JT, Tan L. Novel disease-modifying therapies for Alzheimer's disease. J Alzheimer Dis 31(3): 475-92 (2012).
3. Takizawa C, Thompson PL, van Walsem A, Faure C, Maier WC. Epidemiological and economic burden of Alzheimer's disease: a systematic literature review of data across Europe and the United States of America. J Alzheimer Dis 43(4): 1271-84 (2015).
4. Jiang T, Yu JT, Tian Y, Tan L. Epidemiology and Etiology of Alzheimer's disease: From Genetic to Non-Genetic Factors. Curr Alzheimer Res 10(8): 852-67 (2013).
5. Salmon DP, Lange KL. Cognitive screening and neuropsychological assessment in early Alzheimer's disease. Clin Geriatr Med 17(2): 229-54 (2001).
6. Babic M, Svob Strac D, Muck-Seler D, Pivac N, Stanic G, Hof PR, et al. Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. Croatian Med J 55(4): 347-65 (2014).
7. Johnston JM, Hu WT, Fardo DW, Greco SJ, Perry G, Montine TJ, et al. Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. Curr Alzheimer Res 11(2): 165-74 (2014).
8. O'Bryant SE, Xiao G, Edwards M, Devous M, Gupta VB, Martins R, et al. Biomarkers of Alzheimer's disease among Mexican Americans. J Alzheimers Dis 34(4): 841-9 (2013).
9. Jeong HG, Lim S, Lee JJ, Kim TH, Jang HC, Kim KW. Could serum adiponectin be a useful biomarker for Alzheimer's disease? Asian J Psychiatry 4: S43 (2011).
10. Durakoglugil M, Irving AJ, Harvey J. Leptin induces a novel form of NMDA receptor-dependent long-term depression. J Neurochem 95(2): 396-405 (2005).
11. Greco SJ, Sarkar S, Casadesus G, Zhu X, Smith MA, Ashford JW, et al. Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells. Neurosci Lett 455(3): 191-4 (2009).
12. Tg2567Fewlass DC, Noboa K, Pi-Sunyer FX, Johnston JM, Yan SD, Tezapsidis N. Obesity-related leptin regulates Alzheimer's Abeta. FASEB J 18(15): 1870-8 (2004).
13. Chan KH, Lam KS, Cheng OY, Kwan JS, Ho PW, Cheng KK, et al. Adiponectin is protective against oxidative stress induced cytotoxicity in amyloid-beta neurotoxicity. PloS One 7(12): e52354 (2012).
14. Qiu G, Wan R, Hu J, Mattson MP, Spangler E, Liu S, et al. Adiponectin protects rat hippocampal neurons against excitotoxicity. Age (Dordrecht, Netherlands) 33(2): 155-65 (2011).
15. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 63(7): 1187-92 (2004).
16. Razay G, Vreugdenhil A, Wilcock G. Insulin resistance, dyslipidemia and the risk of Alzheimer's disease: A case control study. Alzheimer's Dement 7(4): S621 (2011).
17. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses. Eur J Epidemiol 25(9): 603-5 (2010).
18. Song F, Sheldon TA, Sutton AJ, Abrams KR, Jones DR. Methods for exploring heterogeneity in meta-analysis. Eval Health Prof 24(2): 126-51 (2001).
19. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 315(7121): 1533-7 (1997).
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109): 629-34 (1997).
21. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4): 1088-101 (1994).
22. Theodoropoulou A, Metallinos IC, Psyrogiannis A, Vagenakis GA, Kyriazopoulou V. Ghrelin and leptin secretion in patients with moderate Alzheimer's disease. J Nutr Health Aging 16(5): 472-7 (2012).
23. Khemka VK, Bagchi D, Bandyopadhyay K, Bir A, Chattopadhyay M, Biswas A, et al. Altered Serum Levels of Adipokines and Insulin in Probable Alzheimer's Disease. J Alzheimers Dis 41(2): 525-33 (2014).
24. Bigalke B, Schreitmuller B, Sopova K, Paul A, Stransky E, Gawaz M, et al. Adipocytokines and CD34 progenitor cells in Alzheimer's disease. PloS One 6(5): e20286 (2011).
25. Baranowska-Bik A, Bik W, Kalisz M, Wolinska-Witort E, Styczynska M, Chodakowska M, et al. Serum adiponectin levels change in a course of Alzheimer's disease. Eur Neuropsychopharmacol 21: S546 (2011).
26. Pavlik V, Massman P, Barber R, Doody R. Differences in the association of peripheral insulin and cognitive function in non-diabetic Alzheimer's disease cases and normal controls. J Alzheimers Dis 34(2): 449-56 (2013).
27. Burns JM, Honea RA, Vidoni ED, Hutfles LJ, Brooks WM, Swerdlow RH. Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging. Biochim Biophys Acta 1822(3): 333-9 (2012).
28. Macesic M, Lalic NM, Kostic VS, Jotic A, Stefanova E, Lalic K, et al. Analysis of insulin sensitivity level and lipid profile in normoglycaemic patients with different stage of cognitive disorder. Diabetes, Stoffwechsel und Herz 20(6): 444 (2011).
29. Isik AT, Bozoglu E. Acetylcholinesterase inhibition and insulin resistance in late onset Alzheimer's disease. Int Psychogeratr 21(6): 1127-33 (2009).
30. Burns JM, Donnelly JE, Anderson HS, Mayo MS, Spencer-Gardner L, Thomas G, et al. Peripheral insulin and brain structure in early Alzheimer disease. Neurology 69(11): 1094-104 (2007).
31. Carantoni M, Zuliani G, Munari MR, D'Elia K, Palmieri E, Fellin R. Alzheimer disease and vascular dementia: relationships with fasting glucose and insulin levels. Dement Geriatr Cogn Disord 11(3): 176-80 (2000).
32. Razay G, Wilcock GK. Hyperinsulinaemia and Alzheimer's disease. Age Ageing 23(5): 396-9 (1994).
33. Meneilly GS, Hill A. Alterations in glucose metabolism in patients with Alzheimer's disease. J Am Geriatr Soc 41(7): 710-4 (1993).
34. Wang C, Yu JT, Wang HF, Jiang T, Tan CC, Meng XF, et al. Meta-analysis of peripheral blood apolipoprotein E levels in Alzheimer's disease. PloS one 9(2): e89041 (2014).
35. Hu N, Tan MS, Yu JT, Sun L, Tan L, Wang YL, et al. Increased expression of TREM2 in peripheral blood of Alzheimer's disease patients. J Alzheimer Dis 38(3): 497-501 (2014).
36. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, et al. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 67(9): 1077-81 (2010).
37. Ewers M, Mielke MM, Hampel H. Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol 45(1): 75-9 (2010).
38. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13(11): 1359-62 (2007).
39. Soodini GR. Adiponectin and leptin in relation to insulin sensitivity. Metab Synd Rel Disord 2(2): 114-23 (2004).
40. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophy Res Commun 257(1): 79-83 (1999).
41. Tasaka Y, Yanagisawa K, Iwamoto Y. Human plasma leptin in obese subjects and diabetics. Endocr J 44(5): 671-6 (1997).
42. Shimizu H, Shimomura Y, Nakanishi Y, Futawatari T, Ohtani K, Sato N, et al. Estrogen increases in vivo leptin production in rats and human subjects. J Endocrinol 154(2): 285-92 (1997).
43. Havel PJ, Kasim-Karakas S, Dubuc GR, Mueller W, Phinney SD. Gender differences in plasma leptin concentrations. Nat Med 2(9): 949-50 (1996).
44. Isidori AM, Strollo F, More M, Caprio M, Aversa A, Moretti C, et al. Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights. J Clin Endocrinol Metabol 85(5): 1954-62 (2000).
45. Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC, et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 52(2): 268-76 (2003).
46. Paz-Filho GJ, Babikian T, Asarnow R, Delibasi T, Esposito K, Erol HK, et al. Leptin replacement improves cognitive development. PloS one 3(8): e3098 (2008).
47. Steppan CM, Swick AG. A role for leptin in brain development. Biochem Biophy Res Commun 256(3): 600-2 (1999).
48. Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, Harris TB, et al. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 302(23): 2565-72 (2009).
49. Holden KF, Lindquist K, Tylavsky FA, Rosano C, Harris TB, Yaffe K. Serum leptin level and cognition in the elderly: Findings from the Health ABC Study. Neurobiol Aging 30(9): 1483-9.(2009).
50. Power DA, Noel J, Collins R, O'Neill D. Circulating leptin levels and weight loss in Alzheimer's disease patients. Dement Geriatr Cogn Disord 12(2): 167-70 (2001).
51. Claxton A, Baker LD, Wilkinson CW, Trittschuh EH, Chapman D, Watson GS, et al. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. J Alzheimer Dis 35(4): 789-97 (2013).
52. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69(1): 29-38 (2012).
53. Bik W, Baranowska-Bik A, Wolinska-Witort E, Kalisz M, Styczynska M, Chodakowska-Zebrowska M, et al. Assessment of adiponectin and its isoforms in elderly women with late onset Alzheimer's disease and mild cognitive impairment. Eur Neuropsychopharmacol 23: S542-S43 (2013).
54. Guler B, Savas S, Sarac F, Akcicek F. Adiponectin, TNF-alpha, ICAM-1, vcam-1 levels and insulin resistance in non-diabetic Alzheimer's disease patients. Eur Geriatr Med 3: S137-S38 (2012).
55. Bik W, Baranowska-Bik A, Styczynska M, Barcikowska M, Wolinska-Witort E, Baranowska B. Adiponectin and glucose homeostasis parameters in women with Alzheimer's disease. J Diabetes 3: 48 (2011).
56. Warren MW, Hynan LS, Weiner MF. Lipids and adipokines as risk factors for Alzheimer's disease. J Alzheimers Dis 29(1): 151-7 (2012).
57. Gonzalez C, Martin T, Cacho J, Brenas MT, Arroyo T, Garcia-Berrocal B, et al. Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Invest 29(7): 637-42 (1999).
58. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D, Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50(1): 164-8 (1998).